Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Prepaid Assets of $242.1 million for Q1 2026, up 58.84% year-on-year from $152.4 million in Q1 2025, and down 14.11% on a QoQ basis from $281.9 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of Prepaid Assets data on file, last reported at $242.1 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 58.84% year-over-year to $242.1 million; the trailing twelve-month figure through Mar 2026 stood at $242.1 million (up 58.84% YoY), and the FY2025 full-year result was $281.9 million, up 141.01% from the prior year.
- Prepaid Assets for Q1 2026 stood at $242.1 million, down from $281.9 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $281.9 million in Q4 2025 and bottomed at $115.1 million in Q1 2022.
- The 5-year median for Prepaid Assets is $145.5 million (2023), against an average of $157.8 million.
- Peak annual rise in Prepaid Assets reached 141.01% in 2025, while the deepest fall reached 24.53% in 2025.
- A 5-year view of Prepaid Assets shows it stood at $132.9 million in 2022, then retreated by 4.92% to $126.4 million in 2023, then slipped by 7.45% to $117.0 million in 2024, then soared by 141.01% to $281.9 million in 2025, then decreased by 14.11% to $242.1 million in 2026.
- The last three Prepaid Assets figures came in at $242.1 million (Q1 2026), $281.9 million (Q4 2025), and $188.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 242.10 Mn |
| Dec 31, 2025 | 281.89 Mn |
| Sep 30, 2025 | 188.04 Mn |
| Jun 30, 2025 | 147.31 Mn |
| Mar 31, 2025 | 152.42 Mn |
| Dec 31, 2024 | 116.96 Mn |
| Sep 30, 2024 | 145.35 Mn |
| Jun 30, 2024 | 154.75 Mn |
| Mar 31, 2024 | 201.96 Mn |
| Dec 31, 2023 | 126.38 Mn |
| Sep 30, 2023 | 157.96 Mn |
| Jun 30, 2023 | 145.45 Mn |
| Mar 31, 2023 | 119.03 Mn |
| Dec 31, 2022 | 132.92 Mn |
| Sep 30, 2022 | 125.52 Mn |
| Jun 30, 2022 | 129.78 Mn |
| Mar 31, 2022 | 115.07 Mn |
| Dec 31, 2021 | 88.08 Mn |
| Sep 30, 2021 | 108.53 Mn |
| Jun 30, 2021 | 94.14 Mn |
| Mar 31, 2021 | 75.98 Mn |
| Dec 31, 2020 | 62.77 Mn |
| Sep 30, 2020 | 74.77 Mn |
| Jun 30, 2020 | 88.35 Mn |
| Mar 31, 2020 | 98.70 Mn |
| Dec 31, 2019 | 80.34 Mn |
| Sep 30, 2019 | 73.54 Mn |
| Jun 30, 2019 | 65.62 Mn |
| Mar 31, 2019 | 81.67 Mn |
| Dec 31, 2018 | 73.71 Mn |
| Sep 30, 2018 | 90.84 Mn |
| Jun 30, 2018 | 51.93 Mn |
| Mar 31, 2018 | 66.67 Mn |
| Dec 31, 2017 | 40.12 Mn |
| Sep 30, 2017 | 30.43 Mn |
| Jun 30, 2017 | 22.03 Mn |
| Mar 31, 2017 | 18.13 Mn |
| Dec 31, 2016 | 21.74 Mn |
| Sep 30, 2016 | 19.28 Mn |
| Jun 30, 2016 | 22.15 Mn |
| Mar 31, 2016 | 27.63 Mn |
| Dec 31, 2015 | 16.56 Mn |
| Sep 30, 2015 | 17.45 Mn |
| Jun 30, 2015 | 15.12 Mn |
| Mar 31, 2015 | 13.21 Mn |
| Dec 31, 2014 | 9.74 Mn |
| Sep 30, 2014 | 10.70 Mn |
| Jun 30, 2014 | 10.27 Mn |
| Mar 31, 2014 | 8.41 Mn |
| Dec 31, 2013 | 3.91 Mn |
| Sep 30, 2013 | 4.78 Mn |
| Jun 30, 2013 | 4.21 Mn |
| Mar 31, 2013 | 3.54 Mn |
| Dec 31, 2012 | 2.64 Mn |
| Sep 30, 2012 | 5.68 Mn |
| Mar 31, 2012 | 7.25 Mn |
| Dec 31, 2011 | 4.16 Mn |
| Sep 30, 2011 | 4.91 Mn |
| Jun 30, 2011 | 5.08 Mn |
| Mar 31, 2011 | 4.92 Mn |
| Dec 31, 2010 | 6.89 Mn |
| Sep 30, 2010 | 6.43 Mn |
| Jun 30, 2010 | 6.02 Mn |
| Dec 31, 2009 | 4.15 Mn |